- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02072746
Zinc Supplementation in Alcoholic Cirrhosis
March 17, 2021 updated by: Matthew Cave, University of Louisville
A Double-Blind, Randomized, Placebo-Controlled Study of the Effects of Daily Oral Zinc Sulfate (220 mg) in Subjects With Alcoholic Cirrhosis
The purpose of this study is to determine if zinc therapy: (1) strengthens your intestine's defensive barrier preventing damaging substances from reaching your liver, (2) decreases liver injury (inflammation, oxidative stress, cell death) and scarring, and (3) improves your liver-related health.
Based on our preliminary animal data and other published reports, we expect zinc therapy to achieve all of these goals.
Zinc is affordable, available over the counter or by prescription, and has an excellent safety profile.
Positive results from this study will show that zinc is a significant therapy for millions of Americans with alcoholic liver disease.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Two-thirds of Americans consume alcohol, and an estimated 14 million Americans are alcoholics.
It has been estimated that 15%-30% of heavy drinkers develop advanced Alcoholic liver disease (ALD).
The prevalence of ALD in the United States is conservatively estimated at 2 million persons.
Nearly 50% of liver-related deaths and 30% of hepatocellular carcinomas in the US are due to alcoholic cirrhosis.
Despite recent advances in our understanding of ALD, there is currently no FDA approved medication for any stage of ALD.
Zinc sulfate is inexpensive, available over the counter, and has an excellent safety profile.
If zinc positively influences the mechanisms postulated to play a role in human ALD, this affordable treatment would become relevant to millions of people worldwide.
Study Type
Interventional
Enrollment (Actual)
30
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Kentucky
-
Louisville, Kentucky, United States, 40202
- University of Louisville
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Ability to provide informed consent.
- Clinical diagnosis of alcoholic cirrhosis.
- Between the ages of 18 years and 70 years.
- Ability to attend all clinic visits and participate in monthly telephone calls.
- Child-Pugh score of A or B.
Exclusion Criteria:
- Allergy or intolerance to zinc sulfate.
- Hospitalization within the previous 28 days.
- Pregnancy.
- Illicit drug use within the past 12 months.
- Infection with hepatitis B, hepatitis C, or HIV.
- Known or suspected cancer within the past 5 years.
- Serum creatinine greater than 1.5 mg/dl within the past month.
- Any severe chronic disease other than liver disease.
- Impairment (slowness) of behavior, intelligence, and neuromuscular function which may indicate hepatic encephalopathy (slow or confused thinking due to your liver disease).
- Participation in another clinical trial.
- Any type of infection within the past month.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Zinc
zinc sulfate 220 mg daily
|
Other Names:
|
Placebo Comparator: Placebo
Placebo study for comparison
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in clinical status
Time Frame: Baseline to 3 months
|
Whether the subject has improved clinically at time point.
|
Baseline to 3 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Blood zinc levels
Time Frame: 0,3,6,12,24 months
|
0,3,6,12,24 months
|
|
Change in serum endotoxin levels
Time Frame: 0,3,6,12,24 months
|
Whether the subject has a change in the serum endotoxin levels.
|
0,3,6,12,24 months
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Matthew Cave, MD, University of Louisville
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
February 1, 2010
Primary Completion (Actual)
March 1, 2011
Study Completion (Actual)
March 1, 2019
Study Registration Dates
First Submitted
February 19, 2014
First Submitted That Met QC Criteria
February 26, 2014
First Posted (Estimate)
February 27, 2014
Study Record Updates
Last Update Posted (Actual)
March 22, 2021
Last Update Submitted That Met QC Criteria
March 17, 2021
Last Verified
March 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Chemically-Induced Disorders
- Digestive System Diseases
- Pathologic Processes
- Alcohol-Related Disorders
- Substance-Related Disorders
- Liver Diseases
- Liver Diseases, Alcoholic
- Alcohol-Induced Disorders
- Fibrosis
- Liver Cirrhosis
- Liver Cirrhosis, Alcoholic
- Physiological Effects of Drugs
- Dermatologic Agents
- Trace Elements
- Micronutrients
- Astringents
- Zinc
- Zinc Sulfate
Other Study ID Numbers
- OICB10007
- K23AA018399 (U.S. NIH Grant/Contract)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alcoholic Cirrhosis
-
Pharmicell Co., Ltd.RecruitingAlcoholic CirrhosisKorea, Republic of
-
Assistance Publique - Hôpitaux de ParisCompletedAlcoholic Hepatitis | Alcoholic CirrhosisFrance
-
University Hospital, MontpellierNarbonne Hospital; University Hospital, NîmesTerminatedAlcoholic Liver Disease | Alcoholic CirrhosisFrance
-
Nantes University HospitalCompleted
-
University Hospital, LilleRecruitingAlcoholic Liver Disease | Severe Alcoholic Hepatitis | Alcoholic CirrhosisFrance
-
Indiana UniversityNational Institute on Alcohol Abuse and Alcoholism (NIAAA); Cedars-Sinai Medical...Recruiting
-
Pharmicell Co., Ltd.CompletedAlcoholic Liver CirrhosisKorea, Republic of
-
Assistance Publique - Hôpitaux de ParisNational Cancer Institute, France; French National Agency for Research on AIDS...Unknown
-
Stempeutics Research Pvt LtdCompletedAlcoholic Liver CirrhosisIndia
-
Yonsei UniversityUnknownAlcoholic Liver CirrhosisKorea, Republic of
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States